Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
Top Cited Papers
Open Access
- 8 March 2023
- journal article
- review article
- Published by Springer Nature in npj Precision Oncology
- Vol. 7 (1) , 1-11
Abstract
Toll-like receptors (TLRs), which serve as a bridge between innate and adaptive immunity, may be viable treatment targets. TLRs are the first line of defense against microbes and activate signaling cascades that induce immune and inflammatory responses. Patients with “hot” versus “cold” tumors may respond more favorably to immune checkpoint inhibition, and through their downstream effects, TLR agonists have the potential to convert “cold tumors” into “hot tumors” making TLRs in combination with immune checkpoint inhibitors, potential targets for cancer therapies. Imiquimod is a topical TLR7 agonist, approved by the FDA for antiviral and skin cancer treatments. Other TLR adjuvants are used in several vaccines including Nu Thrax, Heplisav, T-VEC, and Cervarix. Many TLR agonists are currently in development as both monotherapy and in combination with immune checkpoint inhibitors. In this review, we describe the TLR agonists that are being evaluated clinically as new therapies for solid tumors.Keywords
This publication has 68 references indexed in Scilit:
- Trial WatchOncoImmunology, 2014
- Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trialJournal of Cancer Research and Clinical Oncology, 2014
- Pattern recognition receptors in innate immunity, host defense, and immunopathologyAdvances in Physiology Education, 2013
- Bacillus Calmette–Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccineCancer Science, 2013
- TLR8: the forgotten relative revindicatedCellular & Molecular Immunology, 2012
- Toll-like receptor 9 (TLR9) agonists in the treatment of cancerOncogene, 2008
- TLR signaling by tumor and immune cells: a double-edged swordOncogene, 2008
- Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activitiesEuropean Journal of Immunology, 2003
- The Imidazoquinolines, Imiquimod and R-848, Induce Functional, but Not Phenotypic, Maturation of Human Epidermal Langerhans' CellsClinical Immunology, 2000
- Review Article Imiquimod applied topically: a novel immune response modifier and new class of drugInternational Journal of Immunopharmacology, 1999